ChemSpider 2D Image | PARECOXIB SODIUM | C19H17N2NaO4S

PARECOXIB SODIUM

  • Molecular FormulaC19H17N2NaO4S
  • Average mass392.404 Da
  • Monoisotopic mass392.080658 Da
  • ChemSpider ID7851185

  • Charge - Charge

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

{[4-(5-Méthyl-3-phényl-1,2-oxazol-4-yl)phényl]sulfonyl}(propionyl)azanide de sodium [French] [ACD/IUPAC Name]
198470-85-8 [RN]
EB87433V6F
N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide Sodium Salt
N-[[p-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propionamide Sodium Salt
Natrium-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}(propionyl)azanid [German] [ACD/IUPAC Name]
Parecoxib (sodium salt)
PARECOXIB SODIUM [USAN]
Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-, sodium salt (1:1) [ACD/Index Name]
SODIUM [4-(5-METHYL-3-PHENYL-1,2-OXAZOL-4-YL)BENZENESULFONYL](PROPANOYL)AZANIDE
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

D03717 [DBID]
YM-978 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      COX MedChem Express HY-17474A
      Immunology/Inflammation MedChem Express HY-17474A
      Immunology/Inflammation; MedChem Express HY-17474A
      Parecoxib is a potent and selective COX-2 inhibitor. MedChem Express
      Parecoxib is a potent and selective COX-2 inhibitor.; IC50 value:; Target: COX-2; in vitro: The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue [1].; in vivo: Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days [2]. MedChem Express HY-17474A
      Parecoxib is a potent and selective COX-2 inhibitor.;IC50 value:;Target: COX-2;In vitro: The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue [1].;In vivo: Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days [2]. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision [3]. MedChem Express HY-17474A

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement